JLAB Upgrade Cavities Delivered Ahead of Schedule

Bergisch Gladbach, Germany – April 20, 2010 - RI Research Instruments GmbH, a majority-owned subsidiary of Bruker Energy & Supercon Technologies, Inc. (BEST), today released test result information on the performance of its superconducting radio frequency (rf) cavities recently shipped to the Continuous Electron Beam Accelerator Facility (CEBAF) at Jefferson Lab in Virginia.

In July 2009, RI Research Instruments received an approximately $6 million contract for the supply of 86 superconducting niobium 7-cell 1.5 GHz cavities, covering material procurement, manufacturing, rf optimisation and bulk buffered chemical polishing.



After niobium procurement, manufacturing started in November 2009 and 84 of 86 cavities were completed, delivered and accepted by Jefferson Lab by the middle of December 2010, up to six months ahead of the original schedule, which called for the last cavity delivery in June 2011. The last two cavities were delivered and accepted in March 2011.



Hanspeter Vogel, Managing Director of RI Research Instruments, said that about 25 cavities have been tested at Jefferson Lab to date. He continued, "Today we can report on the strong results of the cavities finally prepared at JLAB and cold tested. All tested cavities have safely exceeded the accelerating field specification of 19.2 MV/m with maximum accelerating gradients beyond 40 MV/m."



For more information, reference presentations at TTC meeting in Milano Italy, February 2011.



"We thank Jefferson Lab for this opportunity to supply CEBAF with our technology and the excellent cooperation throughout the project. We congratulate JLAB on the achievements made so far with the delivered cavities," Mr. Vogel added.



About RI Research Instruments and Bruker Energy & Supercon Technologies, Inc.:
RI Research Instruments GmbH is a world leader in the development and manufacturing of normal and superconducting rf cavities and systems, linear accelerators, as well as special products for physics and energy research, scientific, medical and industrial applications. RI products also include high-performance electron and ion sources, particle beamlines and diagnostics, research reactor subunits as well as vacuum and cryogenic systems. BEST has operations in the US, the UK and Germany, and is a wholly-owned subsidiary of Bruker Corporation (NASDAQ: BRKR).



For more information, please visit: www.research-instruments.de or www.bruker-est.com




CAUTIONARY STATEMENT OF BEST


This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "continue" or other similar words.



These forward-looking statements are predictions, not guarantees. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to materially differ from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those projected, include, but are not limited to, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as guarantees of future events.



The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.





RI Research Instruments Contact:


Dr. Michael Peiniger

Managing Director, RI Research Instruments GmbH

Tel: +49 2204 843676

Email: michael.peiniger@research-instruments.de


Hanspeter Vogel

Managing Director, RI Research Instruments GmbH

Tel: +49 2204 843513

Email: hanspeter.vogel@research-instruments.de